Few days ago, Relmada Therapeutics Inc (OTCMKTS:RLMD) jumped sharply from its base of $2.50 on massive volume to make a 52-week high of $4. Since then RLMD stock has been declining steadily moving close to level from where it started its run. The company was a target of hard mailer promotion promoted by Gramercy Strategic Partners LLC. The compensation for the promotion was $964,391 and the mailer appeared as a newspaper mockup.
The news
Along with the promotion emails, Relmada has been making some big announcements including the latest news of submission of Clinical Trial Application in Canada. It filed the application for its unique Oral Formulations of Buprenorphine. The ongoing projects of the company are compelling and indicate big things to come in the future. Relmada is a late-stage specialty Pharma firm working on innovative forms of proven drug offerings together with other chemical entities that potentially consider the areas of unmet medical need in alleviation of pain.
The portfolio
Relmada Therapeutics Inc (OTCMKTS:RLMD) possess a diversified portfolio of promising drug candidates. It includes four key products which are at various phases of development. It includes lead candidate drug d-Methadone, a treatment for neuropathic pain. The other drug candidates are MepiGel which is an orphan drug designated topical formulation of mepivacaine. The third one is BuTab which is oral dosage version of buprenorphine. Last product is LevoCap ER which is sustained release dosage version of the levorphanol.
The scope
Relmada’s product development measures are supported by the internationally acknowledged scientific expertise of research team. The company wants to mitigate clinical development costs and risks while potentially offering valuable products in key areas of unmet medical needs. Relmada is planning a first stage study to assess the tolerability and safety of BuTab in healthy subjects. It is meant for the cure of both chronic pain and opioid dependence.
